138913-07-2 Usage
Description
4-Pentylbenzamide is a chemical compound with the molecular formula C14H17NO. It is an amide derivative of benzene, characterized by a benzene ring with a pentyl chain attached to the amide group. 4-Pentylbenzamide is known for its potential biological and pharmacological properties, making it a valuable component in various industries and research areas.
Uses
Used in Pharmaceutical Industry:
4-Pentylbenzamide is used as an intermediate in the production of pharmaceuticals for its potential biological and pharmacological properties. It plays a crucial role in the synthesis of various medicinal compounds, contributing to the development of new drugs and therapies.
Used in Organic Synthesis:
In the field of organic synthesis, 4-Pentylbenzamide serves as a key intermediate. It is utilized in the preparation of other organic compounds, showcasing its versatility and importance in chemical reactions and processes.
Used in Chemical Manufacturing:
4-Pentylbenzamide is employed as a precursor in the manufacturing of other chemicals. Its unique structure and properties make it suitable for use in the production of a wide range of chemical products, further expanding its applications across various industries.
Used in Research:
4-Pentylbenzamide is also used in research settings to study its effects on different biological systems. This allows scientists to gain a deeper understanding of its potential applications and to explore new avenues for its use in various fields, such as medicine and biotechnology.
Used in Commercial Products:
4-Pentylbenzamide can be found in some commercial products, where its unique properties contribute to the overall functionality and performance of the final product. This highlights the compound's practical applications and its ability to be integrated into various consumer goods.
Check Digit Verification of cas no
The CAS Registry Mumber 138913-07-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,8,9,1 and 3 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 138913-07:
(8*1)+(7*3)+(6*8)+(5*9)+(4*1)+(3*3)+(2*0)+(1*7)=142
142 % 10 = 2
So 138913-07-2 is a valid CAS Registry Number.
138913-07-2Relevant articles and documents
Cross coupling reactions of organozinc iodides with solid-supported electrophiles: Synthesis of 4-substituted benzoic and 3-substituted (E)- and (Z)-propenoic acids and amides
Oates, Leslie J.,Jackson, Richard F.W.,Block, Michael H.
, p. 140 - 144 (2003)
The solid-supported iodobenzoic acid derivatives 8-10 were coupled with a range of organozinc reagents 1-4 under palladium(o) catalysis. The coupled products released by acidic cleavage with TFA were obtained in high purities after recrystallization. Anal
Potentiation of the fosmidomycin analogue FR 900098 with substituted 2-oxazolines against Francisella novicida
Stephens, Matthew D.,Yodsanit, Nisakorn,Melander, Christian
supporting information, p. 1952 - 1956 (2016/10/22)
A library of 33 compounds was screened for potentiation of the antibiotic FR 900098 against the Francisella tularensis surrogate Francisella novicida. From the screen a highly potent 2-oxazoline adjuvant was discovered capable of potentiating FR 900098 with a 1000-fold reduction in MIC against the Francisella sub-species F. novicida and F. philomiragia.
Discovery and characterization of potent thiazoles versus methicillin- and vancomycin-resistant Staphylococcus aureus
Mohammad, Haroon,Mayhoub, Abdelrahman S.,Ghafoor, Adil,Soofi, Muhammad,Alajlouni, Ruba A.,Cushman, Mark,Seleem, Mohamed N.
, p. 1609 - 1615 (2014/03/21)
Methicillin- and vancomycin-resistant Staphylococcus aureus (MRSA and VRSA) infections are growing global health concerns. Structure-activity relationships of phenylthiazoles as a new antimicrobial class have been addressed. We present 10 thiazole derivatives that exhibit strong activity against 18 clinical strains of MRSA and VRSA with acceptable PK profile. Three derivatives revealed an advantage over vancomycin by rapidly eliminating MRSA growth within 6 h, and no derivatives are toxic to HeLa cells at 11 μg/mL.
